# A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Source: https://onco.cc/trials/nct06412198/  
OnCo record `nct06412198` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of cetuximab, cemiplimab and adagrasib in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations is a phase 1/2, interventional study registered as NCT06412198 by M.D. Anderson Cancer Center, with a registry enrolment figure of 31 participants, started 2024-08-28 and due to reach its primary completion in 2029-03-01. Interventions recorded: Cetuximab; Cemiplimab; Adagrasib. Conditions listed: Metastatic Colorectal Cancer; KRAS G12C Mutations. Primary outcome: Safety and adverse events (AEs). Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of advanced/metastatic microsatellite stable colorectal cancer with KRASG12C mutation with 1+ prior line(s) of therapy". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06412198
- Phase: 1/2
- Setting: A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT06412198: https://clinicaltrials.gov/study/NCT06412198

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Cetuximab](https://onco.cc/drugs/cetuximab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06412198.json